Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02973399 · ClinicalTrials.gov registry record · Phase 1
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
A Phase 1 study, sponsored by Esanex.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02973399 is a Phase 1 study that was terminated before completion, run by Esanex. The registered enrollment target is 5 participants.
The verdict
NCT02973399, a Phase 1 study, was terminated before completion, sponsored by Esanex.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the addition of SNX-5422 to an established dose of ibrutinib will provide clinical response in subjects who have residual disease, but have not progressed on ibrutinib after 18 months of monotherapy, and/or prevents or delays disease progression of subjects with CLL.
Interventions
- DRUG SNX-5422 plus ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-02-07 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02973399
The ClinicalTrials.gov registry entry for NCT02973399 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esanex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNX-5422 plus ibrutinib is the first listed.
NCT02973399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02973399 about?
NCT02973399 is a clinical study titled "Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL". SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the addition of SNX-5422 to an establi...
What is the current status of trial NCT02973399?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-02-07. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT02973399?
The interventions under investigation include: SNX-5422 plus ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02973399?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.